Market Research Logo

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 250 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2014
Analysis of infectious vaccines deal structure
Access to headline, upfront, milestone and royalty data
Access to over 250 infectious vaccines deal records
Identify the most active infectious vaccine dealmakers since 2014
The leading infectious vaccines deals by value since 2014
Includes adjuvant deals and alliances since 2014


In Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 100 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?


  • Executive Summary
  • Introduction
  • Trends in Infectious Vaccines dealmaking
    • Introduction
    • Infectious Vaccines partnering over the years
    • Most active Infectious Vaccines dealmakers
    • Infectious Vaccines partnering by deal type
    • Infectious Vaccines partnering by therapy area
    • Deal terms for Infectious Vaccines partnering
      • Infectious Vaccines partnering headline values
        • Table Infectious Vaccines deals with a headline value
      • Infectious Vaccines deal upfront payments
        • Table Infectious Vaccines deals with an upfront value
      • Infectious Vaccines deal milestone payments
        • Table Infectious Vaccines deals with a milestone value
      • Infectious Vaccines royalty rates
  • Leading Infectious Vaccines deals
    • Introduction
    • Top Infectious Vaccines deals by value
      • Table Top Infectious Vaccines deals by value since 2014
  • Most active Infectious Vaccines dealmakers
    • Introduction
    • Most active Infectious Vaccines dealmakers
    • Most active Infectious Vaccines partnering company profiles
      • National Institute of Allergy and Infectious Diseases
      • Bill and Melinda Gates Foundation
      • Biomedical Advanced Research and Development Authority
      • Emergent BioSolutions
      • GeoVax
      • National Institutes of Health
      • Coalition for Epidemic Preparedness Innovations
      • Department of Defense
      • Astellas Pharma
      • Bavarian Nordic
      • Newlink Genetics
      • Protein Sciences
      • Valneva
      • Infectious Disease Research Institute (IDRI)
      • Inovio Pharmaceuticals
      • Moderna Therapeutics
      • Sanofi-Pasteur
      • Merck and Co
      • MinervaX
      • Profectus Biosciences
      • The International AIDS Vaccine Initiative
      • Affinivax
      • BiondVax
      • Centers for Disease Control and Prevention
      • Defense Threat Reduction Agency
  • Infectious Vaccines contracts dealmaking directory
    • Introduction
    • Infectious Vaccines contracts dealmaking directory
  • Infectious Vaccines dealmaking by technology type
    • Adjuvant
      • Vaccines
      • Attenuated vaccine
      • Conjugate vaccine
      • Inactivated vaccine
      • DNA vaccine
      • Recombinant vector vaccine
      • Subunit vaccine
  • Partnering resource center
    • Online partnering
    • Partnering events
    • Further reading on dealmaking
  • Appendices
    • Infectious Vaccines deals by company A-Z
      • 2A
      • ABIVAX
      • Advanced Biological Laboratories
      • Aelix Therapeutics
      • Aeras
      • Aethlon Medical
      • Affinivax
      • Aldevron
      • American Gene Technologies
      • AnGes MG
      • Antigen Discovery
      • Antitope
      • Appili Therapeutics
      • Aptimmune Biologics
      • Aridis Pharmaceuticals
      • Ark Animal Health
      • Artes Biotechnology
      • Astellas Pharma
      • Avanzcare
      • Batavia Biosciences
      • Bavarian Nordic
      • Baxter International
      • Baylor College
      • Baylor College of Medicine
      • Baylor Institute for Immunology Research
      • Bill and Melinda Gates Foundation
      • BioClones
      • BioCSL
      • Biokinetic Europe
      • Biomedical Advanced Research and Development Authority
      • BiondVax
      • BioNTech
      • BioSun Pharmed
      • Biothera
      • Bio Farma
      • Bpifrance
      • BravoVax
      • Brighton Biotech
      • Broad Institute
      • Burnet Institute
      • Butantan Institute
      • Caliber Biotherapeutics
      • California Institute for Medical Researc
      • Calixar
      • CARB-X
      • Centers for Disease Control and Prevention
      • Center for Genetic Engineering and Biotechnology (Cuba)
      • Cevec Pharmaceuticals
      • Changchun BCHT Biotechnology
      • Children's Hospital Boston
      • China National Biotech Group (CNBG)
      • Cilian
      • CiToxLAB
      • City of Hope
      • ClearPath
      • CMC Biologics
      • Coalition for Epidemic Preparedness Innovations
      • ContraFect
      • Corgenix Medical
      • Create Vaccine Company
      • Crucell
      • CryoPort
      • CSL
      • CureVac
      • D3 Medicine
      • Daiichi Sankyo
      • Defense Advanced Research Projects Agency
      • Defense Threat Reduction Agency
      • Department of Defense
      • Department of Health and Human Services
      • Diavax Biosciences
      • Diaxonhit
      • Duke University
      • DynPort Vaccine Company
      • Eddingpharm
      • Eli Lilly
      • Emergent BioSolutions
      • Emergex Vaccines
      • Emmes
      • Emory University
      • Enesi Pharma
      • Engility
      • Epivax
      • Etna Biotech
      • Etubics
      • Evaxion Biotech
      • Excivion
      • Federal Ministry of Education and Research (BMBF)
      • Fina Biosolutions
      • Finlay Institute
      • Flow Pharma
      • FluGen
      • Fortress Biotech
      • Foundation for Biomedical Research and Innovation
      • Fred Hutchinson Cancer Research Center
      • Fujifilm
      • Fujifilm Diosynth Biotechnologies
      • GC Pharma
      • Genetic Immunity
      • Genexine
      • Genocea Biosciences
      • Genticel
      • GenVec
      • Georgia State University Research Foundation (GSURF)
      • GeoVax
      • GE Healthcare
      • Gilead Sciences
      • GlaxoSmithKline
      • GlaxoSmithKline Biologicals
      • Glide Technologies
      • Global Health Innovative Technology Fund (GHIT)
      • Grameen Health
      • Hawaii Biotech
      • Health Decisions
      • Heat Biologics
      • HemispheRx Biopharma
      • Human Vaccines Project
      • HVIVO
      • IBio
      • IBT Bioservices
      • Ichor Medical Systems
      • IDT Biologika
      • IHI
      • ILiAD Biotechnologies
      • Illumina
      • ImmBio
      • Immune Design
      • Immune Targeting Systems
      • Immunotech Laboratories
      • Immunovaccine
      • Immuron
      • Imperial College London
      • Imutex
      • Indian Council of Medical Research
      • Infectious Disease Research Institute (IDRI)
      • InnaVirVax
      • Innovate UK
      • Innovative Medicines Initiative (IMI)
      • Inovio Pharmaceuticals
      • Inserm
      • Inserm Transfert
      • Institute for Bioscience and Biotechnology Research
      • Institute of Biomedical Research
      • Institut Pasteur
      • Integral Molecular
      • Integrated BioTherapeutics
      • International AIDS Vaccine Initiative
      • International Medica Foundation
      • International Vaccine Institute (IVI)
      • Intravacc
      • Ippox Foundation
      • Israeli National Authority for Technological Innovation
      • Israel Investment Center
      • Janssen Biotech
      • Janssen Pharmaceuticals
      • Jenner Institute
      • Johnson & Johnson
      • JSC Pharmadis
      • KAI Research
      • Kalon Biotherapeutics
      • Kemin Industries
      • King Saud University
      • Laboratorios Liomont
      • Laboratory of Malaria Immunology and Vaccinology (LMIV)
      • La Jolla Institute for Allergy & Immunology
      • Leidos
      • Los Angeles Biomedical Research Institute
      • Louisiana State University
      • Lund University
      • Massachusetts General Hospital
      • Matrivax
      • MediGene
      • MedImmune
      • Merck and Co
      • Merck KGaA
      • Merck Sharpe & Dohme
      • Meridian Life Science
      • Mexican National Technology and Science Council
      • Midatech
      • MilliporeSigma
      • MinervaX
      • Ministry of Finance (China)
      • Ministry of Industry and Information Technology
      • MMS
      • Moderna Therapeutics
      • MSD Wellcome Trust Hilleman Laboratories
      • Mucosis
      • Mundo Sano
      • MyLife Technologies
      • Mymetics
      • Myriad RBM
      • NanoBio
      • NanoPass Technologies
      • Nanotherapeutics
      • National Cancer Institute
      • National Development and Reform Commission
      • National Health and Family Planning Commission
      • National Institutes of Health
      • National Institute of Allergy and Infectious Diseases
      • National Institute of Biomedical Innovation
      • National Institute of Cholera and Enteric Diseases
      • National Institute of Dental and Craniofacial Research (NIDCR)
      • National Research Council Canada
      • National Research Council Industrial Research Assistance Program
      • Naval Medical Research Center
      • Newlink Genetics
      • Noble Life Sciences
      • NovaDigm Therapeutics
      • Novartis
      • Novavax
      • Novo
      • Ohio State University
      • Organic Vaccines
      • Oswaldo Cruz Foundation (Fiocruz)
      • Panacea Biotech
      • Partnership for Influenza Vaccine Introduction
      • PATH (Appropriate Technology in Health)
      • PATH Malaria Vaccine Initiative
      • PaxVax
      • PepTcell
      • Perelman School of Medicine
      • Pevion
      • Pfenex
      • Pfizer
      • PharmaJet
      • PharmAthene
      • PnuVax
      • PPD
      • Probiomed
      • Profectus Biosciences
      • Prokarium
      • Protein Sciences
      • Public Health Agency of Canada
      • Public Health England
      • Qualtran
      • Rapid Micro Biosystems
      • Redbiotec
      • Rockefeller University
      • RSV
      • Sabin Vaccine Institute
      • SAB Therapeutics
      • Sanaria
      • Sanofi-Pasteur
      • Sanofi
      • Scripps Research Institute
      • Seattle Biomed
      • Seattle Children's Hospital
      • SEEK
      • Selecta Biosciences
      • Selexis
      • Sementis
      • Serum Institute of India
      • Sinergium Biotech
      • Sinovac Biotech
      • SK Chemicals
      • Small Business Innovation Research
      • Soligenix
      • Sorrento Therapeutics
      • SRI International
      • Stellar Biotechnologies
      • Sunstone Capital
      • Takeda Pharmaceutical
      • Technical University of Denmark (DTU)
      • TechnoVax
      • Texas Children's Hospital
      • Themis Bioscience
      • Theraclone Sciences
      • The International AIDS Vaccine Initiative
      • Trellis Bioscience
      • Trianni
      • TriLink BioTechnologies
      • Truffle Capital
      • Tulane University
      • Uldic Investment
      • UMN Pharma
      • United States Agency for International Development
      • University of Alberta
      • University of California, San Diego
      • University of Chicago
      • University of Edinburgh
      • University of Guelph
      • University of Hawaii
      • University of Maryland
      • University of Massachusetts
      • University of Miami
      • University of Miami Miller School of Medicine
      • University of Nagasaki
      • University of Nebraska
      • University of Oxford
      • University of Pennsylvania
      • University of Queensland
      • University of Texas
      • University of Tokyo
      • University of Toronto
      • University of Washington
      • US Army
      • US Army Medical Research Institute of Infectious Diseases
      • US Department of Agriculture
      • Valera Pharmaceutical
      • Valneva
      • Vaxart
      • Vaxeal
      • Vaxess Technologies
      • VBI Vaccines
      • Vibalogics
      • Vical
      • Viral Hemorrhagic Fever Consortium
      • Viroclinics Biosciences
      • VirPath
      • Vir Biotechnology
      • Vivaldi Biosciences
      • ViveBio
      • VLP Therapeutics
      • Walter Reed Army Institute of Research
      • WCCT Global
      • Wellcome Trust
      • World Health Organization
      • Xenetic Biosciences
      • Yisheng Biopharma
      • Zoetis
      • Zolovax
      • Zydus Cadila
    • Infectious Vaccines deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Infectious Vaccines deals by deal type
      • Asset purchase
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Contract Services
      • CRADA
      • Development
      • Distribution
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Manufacturing
      • Marketing
      • Option
      • Research
      • Spin out
      • Sub-license
      • Supply
      • Technology transfer
      • Termination
    • Infectious Vaccines deals by therapy area
      • Infectives
      • Bacterial
      • Anthrax
      • Clostridium difficile
      • Escherichia Coli (E-coli)
      • Group A Streptococcus
      • Group B Streptococcus
      • Helicobacter Pylori
      • Methicillin-resistant Staphylococcus aureus (MRSA)
      • Pertussis (Whooping Cough)
      • Salmonella
      • Tuberculosis (TB)
      • Fungal
      • Parasitic
      • Tropical
      • Chikungunya
      • Dengue fever
      • Malaria
      • West Nile Virus
      • Yellow fever
      • Viral
      • Cytomegalovirus
      • Ebola
      • Foot and mouth disease
      • Herpes simplex
      • HIV
      • Influenza
      • Japanese encephalitis
      • Polio
      • Respiratory syncytial virus (RSV)
      • Zika
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report